EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease‐Free Survival

Quentin Le Coent iD, Catherine Legrand iD, James J Dignam, Virginie Rondeau

Biometrical Journal · 2025

DOI: 10.1002/bimj.70064 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Biometrical Journal, 2025. Verfasst von Quentin Le Coent und 3 weiteren Autor:innen. Beteiligte Einrichtung: ISBA/LIDAM, UCLouvain, Louvain-la-Neuve, Belgium. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Biometry, Models, Statistical, Mediation Analysis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fédération Wallonie-Bruxelles, Agence Nationale de la Recherche, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Longitudinal biomarkers constitute a broad class of potential surrogate endpoints in clinical trials. Several approaches have been proposed for surrogate validation but available methods for validating a longitudinal biomarker as a surrogate of a time‐to‐event endpoint such as death remain limited. In this work, we propose a method for validating a longitudinal outcome as a surrogate of a time‐to‐event endpoint using a combination of joint modeling and mediation analysis. The proportion of the total treatment effect on the time‐to‐event endpoint due to its effect on the biomarker is used as a surrogacy measure. This method is developed to integrate meta‐analytic data using a joint model with random effects at both the individual and trial levels. From this model, the indirect treatment effect through the surrogate as well as the direct and total treatment effects is derived using a mediation formula. A simulation study was designed to evaluate the performance of this approach. We applied this method to a multicentric study on prostate cancer to investigate the use of prostate‐specific antigen level as a surrogate for disease‐free survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenBiometryModels, StatisticalMediation AnalysisHumansLongitudinal StudiesDisease-Free SurvivalMaleProstatic NeoplasmsBiomarkers

Stichwörter der Autor:innen

biomarkersjoint modelingmediation analysissurrogacy

Substanzen

Prostate-Specific AntigenBiomarkers

Autor:innen und Institutionen

  • ISBA/LIDAM, UCLouvain, Louvain-la-Neuve, Belgium.
  • Department of Biostatistics, Bordeaux Population Health Research Center, INSERM U1219, Université de Bordeaux, Bordeaux, France.
  • Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA.

ORCID-Profile: Quentin Le Coent, Catherine Legrand

Förderung

  • Fédération Wallonie-Bruxelles
  • Agence Nationale de la Recherche
  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Le Coent, Q., Legrand, C., Dignam, J. J., & Rondeau, V. (2025). Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease‐Free Survival. Biometrical Journal. https://doi.org/10.1002/bimj.70064

Vancouver

Le Coent Q, Legrand C, Dignam JJ, Rondeau V. Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease‐Free Survival. Biometrical Journal. 2025. doi:10.1002/bimj.70064

BibTeX
@article{LeCoent2025,
  author = {Le Coent, Quentin and Legrand, Catherine and Dignam, James J and Rondeau, Virginie},
  title = {Validation of a Longitudinal Marker as a Surrogate Using Mediation Analysis and Joint Modeling: Evolution of the PSA as a Surrogate of the Disease‐Free Survival},
  journal = {Biometrical Journal},
  year = {2025},
  doi = {10.1002/bimj.70064}
}
Kostenlos starten →